Entrada Therapeutics Inc (TRDA) — Cash Flow Reinvestment Rate
Entrada Therapeutics Inc (TRDA) has a Cash Flow Reinvestment Rate of 0.64x as of June 2024, reinvesting $25.43 Million (capex $1.05 Million plus investments $-24.38 Million) from operating cash flow of $39.83 Million. Check Entrada Therapeutics Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Entrada Therapeutics Inc Cash Flow Reinvestment Rate (2023–2023)
Historical reinvestment intensity for Entrada Therapeutics Inc across 1 annual periods. Explore Entrada Therapeutics Inc (TRDA) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Entrada Therapeutics Inc (2023–2023)
Year-by-year capital reinvestment analysis for Entrada Therapeutics Inc. For live market cap and broader valuation context, see Entrada Therapeutics Inc market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2023 | 1.03x | $144.26 Million | $139.80 Million | $5.61 Million | — |